Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$521M |
| 2 |
Becton Dickinson
BDX
|
+$411M |
| 3 |
GE Aerospace
GE
|
+$361M |
| 4 |
IBM
IBM
|
+$305M |
| 5 |
Philip Morris
PM
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCR
CR Bard Inc.
BCR
|
+$455M |
| 2 |
NetEase
NTES
|
+$451M |
| 3 |
Medtronic
MDT
|
+$398M |
| 4 |
NVIDIA
NVDA
|
+$348M |
| 5 |
Netflix
NFLX
|
+$332M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.06% |
| 2 | Technology | 13.71% |
| 3 | Financials | 10.21% |
| 4 | Industrials | 9.72% |
| 5 | Consumer Discretionary | 9.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RDGT
3151
Ridgetech Inc
RDGT
$3.19M
| $184K | ﹤0.01% |
4
| – | – |
|
|
AHPI
3152
DELISTED
Allied Healthcare Products
AHPI
| $184K | ﹤0.01% |
87,950
+11,800
| +15% | +$24.7K |
|
|
REED
3153
DELISTED
Reeds, Inc. Common Stock
REED
| $183K | ﹤0.01% |
2,364
-332
| -12% | -$30.3K |
|
|
NIHD
3154
DELISTED
NII Holdings, Inc. Common Stock
NIHD
| $183K | ﹤0.01% |
+430,438
| New | +$163K |
|
|
GFA
3155
DELISTED
Gafisa S.A.
GFA
| $183K | ﹤0.01% |
+14,500
| New | +$150K |
|
|
ZX
3156
DELISTED
China Zenix Auto Internatl Ltd
ZX
| $180K | ﹤0.01% |
147,800
+14,800
| +11% | +$19.8K |
|
3157
Enlivex Ltd
ENLV
$28.4M
| $178K | ﹤0.01% |
651
+241
| +59% | +$64.2K |
|
|
ORKA
3158
Oruka Therapeutics
ORKA
$7.16B
| $175K | ﹤0.01% |
600
-496
| -45% | -$144K |
|
3159
US Global Investors
GROW
$38.8M
| $174K | ﹤0.01% |
44,600
-147,900
| -77% | -$501K |
|
3160
Spyre Therapeutics
SYRE
$8.98B
| $174K | ﹤0.01% |
1,284
+772
| +151% | +$94.4K |
|
3161
CF Bankshares
CFBK
$235M
| $170K | ﹤0.01% |
11,255
+8,128
| +260% | +$113K |
|
|
EMAN
3162
DELISTED
eMagin Corporation
EMAN
| $169K | ﹤0.01% |
102,300
-20,200
| -16% | -$39.1K |
|
3163
Atlantic American Corp
AAME
$29M
| $168K | ﹤0.01% |
49,400
+1,000
| +2% | +$3.48K |
|
3164
Xtant Medical Holdings
XTNT
$43.8M
| $167K | ﹤0.01% |
24,324
+14,425
| +146% | +$114K |
|
3165
Traws Pharma
TRAW
$9.14M
| $164K | ﹤0.01% |
19
-2
| -10% | -$20.6K |
|
3166
Retractable Technologies
RVP
$20.3M
| $163K | ﹤0.01% |
239,800
+99,400
| +71% | +$63.8K |
|
|
RYZ
3167
Ryerson Holding Corp
RYZ
$1.5B
| $163K | ﹤0.01% |
15,700
-261,800
| -94% | -$2.44M |
|
|
PW
3168
Power REIT
PW
$2.93M
| $161K | ﹤0.01% |
2,620
+80
| +3% | +$4.93K |
|
|
CPAC
3169
Cementos Pacasmayo
CPAC
$1.03B
| $160K | ﹤0.01% |
+12,933
| New | +$162K |
|
|
CCRN
3170
DELISTED
Cross Country Healthcare
CCRN
| $156K | ﹤0.01% |
+12,200
| New | +$161K |
|
3171
Inspired Entertainment
INSE
$164M
| $156K | ﹤0.01% |
+15,900
| New | +$171K |
|
3172
Centrus Energy
LEU
$3.83B
| $154K | ﹤0.01% |
38,300
-8,167
| -18% | -$33K |
|
3173
Arcadia Biosciences
RKDA
$1.24M
| $152K | ﹤0.01% |
691
+516
| +295% | +$112K |
|
|
WRN
3174
Western Copper and Gold
WRN
$541M
| $151K | ﹤0.01% |
149,900
+112,800
| +304% | +$114K |
|
|
HOS
3175
DELISTED
Hornbeck Offshore Services, Inc.
HOS
| $151K | ﹤0.01% |
+48,440
| New | +$176K |
|
Similar funds
Jim Simons's Q4 2017 Portfolio in Review
As of Q4 2017, Jim Simons held 3,692 positions worth $90.7B, up 6.7% from $85B the previous quarter. Its ten largest holdings account for 8.4% of the portfolio.
Jim Simons's Q4 2017 filing shows 521 new, 1,724 increased, 1,031 reduced and 386 closed positions. Its largest new stake was Alphabet (Google) Class C: 3,773,700 shares worth $197M. The largest sale was CR Bard Inc., an estimated $455M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q4 2017 buy was Alphabet (Google) Class C: 3,773,700 shares worth $197M.
- Jim Simons added most to ExxonMobil in Q4 2017, an estimated $521M increase.
- Jim Simons's biggest Q4 2017 reduction was NetEase, cutting an estimated $451M.
- Jim Simons fully exited CR Bard Inc. in Q4 2017, selling an estimated $455M.
- Jim Simons's ten largest holdings make up 8.4% of its $90.7B portfolio in Q4 2017.
- Jim Simons opened 521 new positions and closed 386 in Q4 2017.
- Jim Simons's portfolio value rose 6.7% quarter-over-quarter to $90.7B.
Based on Renaissance Technologies's 13F filing for Q4 2017, filed 13 Feb 2018.